Clinical Studies Show REMICADE® Reduces Incidence Of Bowel Surgeries In Ulcerative Colitis Patients

Clinical data presented at the annual meeting of the American College of Gastroenterology (ACG) show that REMICADE® significantly reduces the incidence of colectomy surgeries for patients with moderately to severely active ulcerative colitis (UC). According to a primary analysis of long-term extension data from the Active Ulcerative Colitis 1 and 2 trials (ACT trials), there is a 43 percent reduction in the incidence of colectomy, the surgical removal of the colon, in patients receiving REMICADE® through 54 weeks, compared to those receiving placebo (p=0.012). REMICADE® is the first and only biologic approved for the treatment of ulcerative colitis.